HEALEY ALS Platform Trial - Regimen G DNL343

第2/3相 完了 NCT05842941

概要

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen G will evaluate the safety and efficacy of a single study drug, DNL343, in participants with ALS.

Disease Progression as Assessed by the ALSFRS-R-Slope

Baseline to 24 Weeks · Percent change

Mortality Event Rate

Baseline to 24 weeks · Events per month

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Ed — Shionogi
• Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
• Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
• Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
• Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Shionogi

すべての治験